A brief outpatient procedure that delivers electrical pulses to the lining of the small intestine helped 12 out of 14 Type 2 diabetes patients stop using insulin entirely — and stay off it for a full year. The early-stage results, from Amsterdam University Medical Center in the Netherlands, are drawing serious attention from the global diabetes research community.
At a glance
- Duodenal mucosal resurfacing: The procedure takes about an hour and targets the duodenum, the first section of the small intestine, using a catheter that delivers controlled electrical pulses to the mucosal lining.
- Insulin discontinuation rate: Roughly 86% of trial participants maintained good glycemic control without insulin for 12 months — compared to about 20% for semaglutide alone.
- Disease-modifying potential: Researchers believe the procedure reverses insulin resistance at its root by prompting the duodenum’s tissue to regenerate and respond more effectively to the body’s own insulin.
Why the gut matters in diabetes
The idea that the small intestine plays a role in Type 2 diabetes came partly from an unexpected source: gastric bypass surgery. Clinicians noticed that patients often regained insulin sensitivity almost immediately after the operation — well before they lost significant weight. That observation pointed toward the duodenum as a key player in metabolic regulation.
PhD student Celine Busch and gastroenterology professor Dr. Jacques Bergman at Amsterdam University Medical Center followed that lead. Their theory: a long-term diet high in sugar and calories gradually alters the mucosal lining of the duodenum, which in turn impairs the body’s ability to respond to its own insulin. If that tissue could be renewed, insulin resistance might ease.
Duodenal mucosal resurfacing, or DMR, does exactly that. A specialized catheter delivers alternating electrical pulses to the duodenum’s inner lining, creating a controlled, shallow injury. The tissue regenerates, and with it, the insulin response appears to improve — at least in patients who still produce some insulin of their own.
What the trial found
Fourteen participants underwent the one-hour endoscopic procedure under sedation and went home the same day. They followed a calorie-controlled liquid diet for two weeks, then began taking semaglutide — a widely used diabetes medication — with dosage gradually increasing to 1 mg per week.
After 12 months, 12 of the 14 participants had maintained healthy blood sugar levels without insulin. That 86% rate is a striking contrast to what semaglutide alone typically achieves: insulin discontinuation in roughly one in five patients.
“The potential for controlling diabetes with a single endoscopic treatment is spectacular,” Busch said. Dr. Bergman described the procedure as “disease-modifying” because it targets insulin resistance itself — the underlying driver of Type 2 diabetes — rather than just managing symptoms.
What comes next
The study was funded by Endogenex, a Minnesota-based company that owns the DMR technology. Dr. Bergman serves on Endogenex’s advisory board. Both facts are worth noting: industry-funded studies and advisory relationships can shape how results are framed, and the next phase of research will need to stand up to more independent scrutiny.
That next phase is already in planning. The team is preparing a double-blind randomized controlled trial — the gold standard for medical evidence — to test whether the results hold across a larger, more diverse population.
Some experts are watching carefully. Dr. Kenneth Snow, an endocrinologist and clinical professor of medicine at the University of Washington, described his outlook as cautious optimism. He noted that Type 2 diabetes is a complex, multifaceted condition, and that longer-term safety and efficacy data are still needed. Risks flagged by researchers include bleeding, infection, and possible damage to surrounding tissue — all standard concerns for any endoscopic procedure.
Availability is another real constraint. DMR is currently offered at only a small number of medical centers worldwide, which means even if the larger trial succeeds, equitable access will be a challenge — particularly for the many people managing Type 2 diabetes in lower-income countries and underserved communities.
A new direction for a widespread condition
Type 2 diabetes affects more than 37 million people in the U.S. alone and hundreds of millions more globally. Current standard treatments — glucose-lowering medications and insulin injections — are effective for many patients but carry real burdens: daily administration, side effects like hypoglycemia and weight gain, and ongoing cost.
A one-time outpatient procedure that resets the body’s own insulin response would represent a meaningful shift in how the disease is managed. “DMR is a promising new therapy that could potentially help millions of people with Type 2 diabetes who struggle to manage their blood sugar levels with traditional medications,” Busch said.
The results are preliminary. Fourteen patients is a small cohort, and science advances through replication. But the 86% success rate, combined with a plausible biological explanation, gives researchers a solid foundation to build on. The randomized controlled trial will be the real test — and the diabetes community is watching.
Read more
For more on this story, see: The Brighter Side of News
For more from Good News for Humankind, see:
- Indigenous land rights win at COP30: 160 million hectares recognized
- Ghana establishes marine protected area at Cape Three Points
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
